Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients

Journal of Cachexia, Sarcopenia and Muscle

Volumn , Issue , 2015, Pages 53-61

  Stephens, Nathan A ^a   Skipworth, Richard J E ^a   Gallagher, Iain J ^a   Greig, Carolyn A ^a   Guttridge, Denis C ^b   Ross, James A ^a   Fearon, Kenneth C H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Cachexia; Cancer; Skeletal muscle; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; BETA DYSTROGLYCAN; BETA SARCOGLYCAN; BIOLOGICAL MARKER; DYSTROPHIN; GABARAPL1 PROTEIN; MEMBRANE PROTEIN; MYOSIN HEAVY CHAIN; PROTEIN BNIP3; PROTEIN KINASE B; TRANSCRIPTION FACTOR FOXO; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AUTOPHAGY; BILE DUCT CANCER; BODY WEIGHT; CACHEXIA; CANCER PATIENT; CANCER SURGERY; CATABOLISM; COHORT ANALYSIS; COMMON BILE DUCT; COMMON BILE DUCT CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ESOPHAGOGASTRIC CANCER; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE BIOPSY; MUSCLE METABOLISM; PANCREAS CANCER; PILOT STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECTUS ABDOMINIS MUSCLE; SKELETAL MUSCLE; SMALL INTESTINE CANCER; STOMACH CANCER; UPPER GASTROINTESTINAL CANCER; UPPER GASTROINTESTINAL TRACT; WEIGHT REDUCTION; WESTERN BLOTTING;

EID: 84982182171     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12005     Document Type: Article

References (32)

1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489–95.
2. Tan BH, Ross JA, Kaasa S, Skorpen F, Fearon KC. Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review. J Genet 2011; 90: 165–77.
3. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, Butts CA, Scarfe AG, Sawyer MB. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007; 13: 3264–8.
4. Stephens NA, Skipworth RJ, Fearon KC. Cachexia, survival and the acute phase response. Curr Opin Support Palliat Care 2008; 2: 267–74.
5. Deans DA, Tan BH, Wigmore SJ, Ross JA, de Beaux AC, Paterson-Brown S, Fearon KC. The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br J Cancer 2009; 100: 63–9.
6. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004; 18: 39–51.
7. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, Guttridge DC. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004; 114: 370–8.
8. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294: 1704–8.
9. Zhao J, Brault JJ, Schild A, Goldberg AL. Coordinate activation of autophagy and the proteasome pathway by FOXO transcription factor. Autophagy 2008; 4: 378–80.
10. Clarke BA, Drujan D, Willis MS, Murphy LO, Corpina RA, Burova E, Rakhilin SV, Stitt TN, Patterson C, Latres E, Glass DJ. The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab 2007; 6: 376–85.
11. Skipworth RJ, Stewart GD, Bhana M, Christie J, Sturgeon CM, Guttridge DC, Cronshaw AD, Fearon KC, Ross JA. Mass spectrometric detection of candidate protein biomarkers of cancer cachexia in human urine. Int J Oncol 2010; 36: 973–82.
12. Felix K, Fakelman F, Hartmann D, Giese NA, Gaida MM, Schnolzer M, Flad T, Buchler MW, Werner J. Identification of serum proteins involved in pancreatic cancer cachexia. Life Sci 2011; 88: 218–25.
13. Weber MA, Kinscherf R, Krakowski-Roosen H, Aulmann M, Renk H, Kunkele A, Edler L, Kauczor HU, Hildebrandt W. Myoglobin plasma level related to muscle mass and fiber composition: a clinical marker of muscle wasting? J Mol Med (Berl) 2007; 85: 887–96.
14. Stephens NA, Gallagher IJ, Rooyackers O, Skipworth RJ, Tan BH, Marstrand T, Ross JA, Guttridge DC, Lundell L, Fearon KC, Timmons JA. Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. Genome Med 2010; 2: 1.
15. Ransohoff DF. Cancer. Developing molecular biomarkers for cancer. Science 2003; 299: 1679–80.
16. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. FOXO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399–412.
17. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001; 3: 1014–9.
18. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del PP, Burden SJ, Di LR, Sandri C, Zhao J, Goldberg AL, Schiaffino S, Sandri M. FOXO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007; 6: 458–71.
19. Mammucari C, Schiaffino S, Sandri M. Downstream of Akt: FOXO3 and mTOR in the regulation of autophagy in skeletal muscle. Autophagy 2008; 4: 524–6.
20. Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, Carathers M, Ringel MD, Skipworth RJ, Fearon KC, Hollingsworth MA, Muscarella P, Burghes AH, Rafael-Fortney JA, Guttridge DC. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 2005; 8: 421–32.
21. Cohen S, Brault JJ, Gygi SP, Glass DJ, Valenzuela DM, Gartner C, Latres E, Goldberg AL. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol 2009; 185: 1083–95.
22. All Party Parliamentary Group On Cancer. Report of the All Party Parliamentary Group on Cancer's Inquiry into Inequalities in Cancer. 2009. http://www.macmillan.org.uk/Documents/GetInvolved/Campaigns/APPG/BritainAgainstCancer2009/CancerInequalitiesReport.pdf Accessed 19 May 2014.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method. Methods 2001; 25: 402–8.
24. Schmitt TL, Martignoni ME, Bachmann J, Fechtner K, Friess H, Kinscherf R, Hildebrandt W. Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia. J Mol Med (Berl) 2007; 85: 647–54.
25. Gallagher IJ, Stephens NA, Macdonald AJ, Skipworth RJ, Husi H, Greig CA, Ross JA, Timmons JA, Fearon KC. Suppression of skeletal muscle turnover in cancer cachexia: evidence from the transcriptome in sequential human muscle biopsies. Clin Cancer Res 2012; 18: 2817–27.
26. Doucet M, Russell AP, Leger B, Debigare R, Joanisse DR, Caron MA, LeBlanc P, Maltais F. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 261–9.
27. Vogiatzis I, Simoes DC, Stratakos G, Kourepini E, Terzis G, Manta P, Athanasopoulos D, Roussos C, Wagner PD, Zakynthinos S. Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD. Eur Respir J 2010; 36: 301–10.
28. Ljubicic V, Miura P, Burt M, Boudreault L, Khogali S, Lunde JA, Renaud JM, Jasmin BJ. Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in MDX mouse skeletal muscle. Hum Mol Genet 2011; 20: 3478–93.
29. Lapidos KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 2004; 94: 1023–31.
30. Cosper PF, Leinwand LA. Myosin heavy chain is not selectively decreased in murine cancer cachexia. Int J Cancer 2012; 130: 2722–7.
31. Rennie MJ, Selby A, Atherton P, Smith K, Kumar V, Glover EL, Philips SM. Facts, noise and wishful thinking: muscle protein turnover in aging and human disuse atrophy. Scand J Med Sci Sports 2010; 20: 5–9.
32. Greenhaff PL, Karagounis LG, Peirce N, Simpson EJ, Hazell M, Layfield R, Wackerhage H, Smith K, Atherton P, Selby A, Rennie MJ. Disassociation between the effects of amino acids and insulin on signaling, ubiquitin ligases, and protein turnover in human muscle. Am J Physiol Endocrinol Metab 2008; 295: E595–E604.